IL281608B2 - Antibodies against human CD45RC and their use - Google Patents

Antibodies against human CD45RC and their use

Info

Publication number
IL281608B2
IL281608B2 IL281608A IL28160821A IL281608B2 IL 281608 B2 IL281608 B2 IL 281608B2 IL 281608 A IL281608 A IL 281608A IL 28160821 A IL28160821 A IL 28160821A IL 281608 B2 IL281608 B2 IL 281608B2
Authority
IL
Israel
Prior art keywords
seq
lcvr
antibody
binding fragment
hcvr
Prior art date
Application number
IL281608A
Other languages
English (en)
Hebrew (he)
Other versions
IL281608B1 (en
IL281608A (en
Inventor
Carole Guillonneau
Ignacio Anegon
Original Assignee
Inst Nat Sante Rech Med
Univ Nantes
Ct Hospitalier Universitaire Nantes
Carole Guillonneau
Ignacio Anegon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Nantes, Ct Hospitalier Universitaire Nantes, Carole Guillonneau, Ignacio Anegon filed Critical Inst Nat Sante Rech Med
Publication of IL281608A publication Critical patent/IL281608A/en
Publication of IL281608B1 publication Critical patent/IL281608B1/en
Publication of IL281608B2 publication Critical patent/IL281608B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL281608A 2018-09-21 2019-09-20 Antibodies against human CD45RC and their use IL281608B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306230.6A EP3626265A1 (en) 2018-09-21 2018-09-21 Anti-human cd45rc antibodies and uses thereof
PCT/EP2019/075374 WO2020058495A1 (en) 2018-09-21 2019-09-20 Anti-human cd45rc antibodies and uses thereof

Publications (3)

Publication Number Publication Date
IL281608A IL281608A (en) 2021-05-31
IL281608B1 IL281608B1 (en) 2025-12-01
IL281608B2 true IL281608B2 (en) 2026-04-01

Family

ID=63713787

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281608A IL281608B2 (en) 2018-09-21 2019-09-20 Antibodies against human CD45RC and their use

Country Status (13)

Country Link
US (2) US12168694B2 (cg-RX-API-DMAC7.html)
EP (2) EP3626265A1 (cg-RX-API-DMAC7.html)
JP (2) JP7796531B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210070303A (cg-RX-API-DMAC7.html)
CN (1) CN113164595A (cg-RX-API-DMAC7.html)
AU (1) AU2019343746C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021005276A2 (cg-RX-API-DMAC7.html)
CA (1) CA3113562A1 (cg-RX-API-DMAC7.html)
IL (1) IL281608B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021003281A (cg-RX-API-DMAC7.html)
NZ (1) NZ774030A (cg-RX-API-DMAC7.html)
SG (1) SG11202102659RA (cg-RX-API-DMAC7.html)
WO (1) WO2020058495A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3626265A1 (en) * 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
US20230147657A1 (en) * 2020-03-20 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Chimeric antigen receptor specific for human cd45rc and uses thereof
PL4401842T3 (pl) * 2021-09-16 2025-11-24 Aboleris Pharma Domeny wiążące przeciwko ludzkiemu CD45RC i ich zastosowania
CA3240875A1 (en) 2021-12-23 2023-06-29 Stefanie Urlinger Discernible cell surface protein variants of cd45 for use in cell therapy
EP4637928A1 (en) 2022-12-23 2025-10-29 Cimeio Therapeutics AG Antibodies targeting cd45

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016016442A1 (en) * 2014-08-01 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド N末端にアミノ安息香酸単位を有するオーリスタチン
EP1898529A1 (en) 2005-06-28 2008-03-12 Pioneer Corporation Broadcast receiving apparatus, interference detecting apparatus and interference detecting method
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
AU2006294644A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
ES2642787T3 (es) 2005-10-21 2017-11-20 Lfb Usa, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
FR3003171B1 (fr) 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
EP3626265A1 (en) * 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016016442A1 (en) * 2014-08-01 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOUCOULT L, ET AL,, JCI INSIGHT - TRANSIENT ANTIBODY TARGETING OF CD45RC INDUCES TRANSPLANT TOLERANCE AND POTENT ANTIGEN-SPECIFIC REGULATORY T CELLS, 9 February 2017 (2017-02-09) *
ELODIE PICARDA ET AL,, TRANSIENT ANTIBODY TARGETING OF CD45RC INDUCES TRANSPLANT TOLERANCE AND POTENT ANTIGEN-SPECIFIC REGULATORY T CELLS, 9 February 2017 (2017-02-09) *
RUDIKOFF S ET AL,, SINGLE AMINO ACID SUBSTITUTION ALTERING ANTIGEN-BINDING SPECIFICITY, 1 March 1982 (1982-03-01) *

Also Published As

Publication number Publication date
BR112021005276A2 (pt) 2021-07-13
IL281608B1 (en) 2025-12-01
US20220033500A1 (en) 2022-02-03
WO2020058495A1 (en) 2020-03-26
MX2021003281A (es) 2021-08-11
AU2019343746C1 (en) 2026-04-02
SG11202102659RA (en) 2021-04-29
JP7796531B2 (ja) 2026-01-09
US20250122300A1 (en) 2025-04-17
CA3113562A1 (en) 2020-03-26
AU2019343746A1 (en) 2021-04-15
CN113164595A (zh) 2021-07-23
IL281608A (en) 2021-05-31
AU2019343746B2 (en) 2025-12-04
JP2022502024A (ja) 2022-01-11
KR20210070303A (ko) 2021-06-14
NZ774030A (en) 2026-03-27
JP2025164963A (ja) 2025-10-31
EP3852802A1 (en) 2021-07-28
US12168694B2 (en) 2024-12-17
EP3626265A1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
ZA202004494B (en) Anti-tmprss2 antibodies and antigen-binding fragments
IL282968A (en) Anti-NKG2A antibodies and their use
ZA202004827B (en) Anti-cd73 antibodies and uses thereof
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
IL275734B (en) Anti-pd-l1 antibodies and uses thereof
IL281272A (en) Humanized antibodies against C5 and their uses
IL275826A (en) Anti-mct1 antibodies and their uses
ZA201701920B (en) Anti-human il-17 monoclonal antibodies and use thereof
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
SG11202103095RA (en) Anti-human vsig4 antibodies and uses thereof
IL276548A (en) Binding antibodies - BCMA and their uses
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
SG11202105161YA (en) Anti-il-27 antibodies and uses thereof
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
ZA202100714B (en) Anti-npr1 antibodies and uses thereof
SG11202100663VA (en) Anti-cxcr2 antibodies and uses thereof
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
SG11202102659RA (en) Anti-human cd45rc antibodies and uses thereof
HRP20260007T1 (hr) Humanizirano antitijelo protiv il17a i njegova uporaba
IL277296A (en) Antibodies against PFRH5 and their antigen-binding fragments
SG11202008707YA (en) Anti-il-27 antibodies and uses thereof
SG11202012680TA (en) Anti-l1cam antibodies and uses thereof
ZA202004784B (en) Humanized and de-immunized antibodies
IL283926B1 (en) Antibodies against alpha-synuclein and their uses
SG11202103849TA (en) Anti-periostin antibodies and uses thereof